
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Guard Therapeutics is developing innovative therapies focusing on kidney diseases. The companys lead clinical asset, RMC-035, is in phase 2b development for the prevention and treatment of kidney injuries in patients undergoing open heart surgery. The company also has preclinical candidate drugs intended for the treatment of chronic kidney disease, targeting specific disease segments such as FSGS, IgAN, Alport Syndrome and DKD. Listed on Nasdaq First North Growth Market
Guard therapeutics operates in the Biotechnology research industry.
Guard therapeutics's revenue is 11m - 100m
Guard therapeutics has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.